Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL

Journal of Medicinal Chemistry

Volumn 50, Issue 4, 2007, Pages 641-662

  Bruncko, Milan ^a   Oost, Thorsten K ^a   Belli, Barbara A ^b   Ding, Hong ^a   Joseph, Mary K ^a   Kunzer, Aaron ^a   Martineau, Darlene ^b   McClellan, William J ^a   Mitten, Michael ^a   Ng, Shi Chung ^a   Nimmer, Paul M ^a   Oltersdorf, Tilman ^b   Park, Cheol Min ^a   Petros, Andrew M ^a   Shoemaker, Alexander R ^a   Song, Xiaohong ^a   Wang, Xilu ^a   Wendt, Michael D ^a   Zhang, Haichao ^a   Fesik, Stephen W ^a   Rosenberg, Saul H ^a   Elmore, Steven W ^a   more..

^a ABBOTT LABORATORIES   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIPERAZINE DERIVATIVE; PROTEIN BCL 2; PROTEIN BCL XL; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHEMICAL REACTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; HYDROPHOBICITY; LYMPHOMA; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BCL-X PROTEIN; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LYMPHOMA; MICE; MICE, SCID; MODELS, MOLECULAR; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TRANSPLANTATION, HETEROLOGOUS;

EID: 33847404358     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061152t     Document Type: Article

References (36)

1. McDonald, E. R., III; El-Deiry, W. S. Mammalian cell death pathways: intrinsic and extrinsic. Death Recept. Cancer Ther. 2005, 1-41.
2. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70.
3. Cory, S.; Adams, J. M. The Bcl2 family: regulators of the cellular lite-or-death switch. Nat. Rev. Cancer 2002, 2, 647-656.
4. Borner, C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol. Immunol. 2003, 39, 615-647.
5. van Delft, M. F.; Huang, D. C. S. How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res. 2006, 16, 203-213.
6. Boatright, K. M.; Salvesen, G. S. Mechanisms of caspase activation. Curr. Opin. Cell Biol. 2003, 15, 725-731.
7. Shi, Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell 2002, 9, 459-470.
8. Green, D. R.; Evan, G. I. A matter of life and death. Cancer Cell 2002, 1, 19-30.
9. Amundson, S. A.; Myers, T. G.; Scudiero, D.; Kitada, S.; Reed, J. C. et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 2000, 60, 6101-6110.
10. Muchmore, S. W.; Sattler, M.; Liang, H.; Meadows, R. P.; Harlan, J. E. et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature (London, U.K.) 1996, 381, 335-341.
11. Petros, A. M.; Medek, A.; Nettesheim, D. G.; Kim, D. H.; Yoon, H. S. et al. Solution structure of the antiapoptotic protein bcl-2. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3012-3017.
12. Denisov, A. Y.; Madiraju, M. S. R.; Chen, G.; Khadir, A.; Beauparlant, P. et al. Solution Structure of Human BCL-w: Modulation of Ligand Binding by the C-Terminal Helix. J. Biol. Chem. 2003, 278, 21124-21128.
13. Day, C. L.; Chen, L.; Richardson, S. J.; Harrison, P. J.; Huang, D. C. S. et al. Solution Structure of Prosurvival Mcl-1 and Characterization of Its Binding by Proapoptotic BH3-only Ligands. J. Biol. Chem. 2005, 280, 4738-4744.
14. Sattler, M.; Liang, H.; Nettesheim, D.; Meadows, R. P.; Harlan, J. E. et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997, 275, 983-986.
15. Petros, A. M.; Nettesheim, D. G.; Wang, Y.; Olejniczak, E. T.; Meadows, R. P. et al. Rationale for Bcl-x(L)/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci. 2000, 9, 2528-2534.
16. Walensky, L. D.; Kung, A. L.; Escher, I.; Malia, T. J.; Barbuto, S. et al. Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix. Science (Washington, DC) 2004, 305, 1466-1470.
17. Elmore, S. W.; Oost, T. K.; Park, C.-M. Inhibitors of anti-apoptotic proteins for cancer therapy. Annu. Rep. Med. Chem. 2005, 40, 245-262.
18. Wendt, M. D.; Wang, S.; Kunzer, A.; McClellan, W. J.; Bruncko, M. et al. Discovery and Structure-Activity Relationship of Antagonists of B-Cell Lymphoma 2 Family Proteins with Chemopotentiation Activity in Vitro and in Vivo. J. Med. Chem. 2006, 49, 1165-1181.
19. Shoemaker, A. R.; Oleksijew, A.; Bauch, J.; Belli, B. A.; Borre, T. et al. A Small-Molecule Inhibitor of Bcl-XL Potentiates the Activity of Cytotoxic Drugs In vitro and In vivo. Cancer Res. 2006, 66, 8731-8739.
20. Petros, A. M.; Olejniczak, E. T.; Fesik, S. W. Structural biology of the Bcl-2 family of proteins. Biochim. Biophys. Acta, Mol. Cell Res. 2004, 1644, 83-94.
21. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (London, U.K.) 2005, 435, 677-681.
22. Taylor, E. C.; Skotnicki, J. S. A convenient synthesis of 1-Aryl-4-piperidones. Synthesis 1981, 606-608.
23. Manikandan, S.; Jayashankaran, J.; Raghunalhan, R. An Easy Access to Spiroisoxazoline [5,3] Flavan-4-one through 1,3-Dipolar Cycloaddition Reaction of Nitrile Oxide to Unusual Dipolarophiles. Synth. Commun. 2003, 33, 4063-4069.
24. Zaman, S.; Mitsuru, K.; Abell, A. D. Synthesis of Trisubstituted Imidazoles by Palladium-Catalyzed Cyclization of O-Pentafluorobenzoylamidoximes: Application to Amino acid Mimetics with a C-Terminal Imidazole. Org. Lett. 2005, 7, 609-611.
25. Kubota, D.; Ishikawa, M.; Yamamoto, M.; Murakami, S.; Hachisu, M. et al. Tricyclic pharmacophore-based molecules as novel integrin avb3 antagonists. Part I: Design and synthesis of a lead compound exhibiting avb3/aIIbb3 dual antagonistic activity. Bioorg. Med. Chem. 2006, 14, 2089-2108.
26. Augeri, D. J.; Baumeister, S. A.; Bruncko, M.; Dickman, D. A.; Ding, H. et al. Preparation of N-arylcarbonyl- and heteroarylcarbonyl benzenesulfonamide inhibitors of Bcl-Xl and Bcl-2 as promoters of apoptosis. US Pat. Appl. 957,276, pub. July 4, 2002.
27. Nunez, G.; London, L.; Hockenbery, D.; Alexander, M.; McKearn, J. P. et al. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J. Immunol. 1990, 144, 3602-3610.
28. Greco, F. A. Oral etoposide in lymphoma. Drugs 1999, 58, 35-41.
29. Gordon, L. I.; Young, M.; Weller, E.; Habermann, T. M.; Winter, J. N. et al. A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity. Blood 1999, 94, 3307-3314.
30. Moskowitz, C. H.; Bertino, J. R.; Classman, J. R.; Hedrick, E. E.; Hunte, S. et al. Ifosfamide. carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 1999, 17, 3776-3785.
31. Koshland, D. E.; Jr. Application of a theory of enzyme specificity to protein synthesis. Proc. Natl. Acad. Sci. U.S.A. 1958, 44, 98-105.
32. Bursavich, M. G.; Rich, D. H. Designing Non-Peptide Peptidomimetics in the 21st Century: Inhibitors Targeting Conformational Ensembles. J. Med. Chem. 2002, 45, 541-558.
33. Goh, C.-S.; Milburn, D.; Gerstein, M. Conformational changes associated with protein-protein interactions. Curr. Opin. Struct. Biol. 2004, 14, 104-109.
34. Brunger, A. T. X-PLOR Version 3.1.: Yale University Press: New Haven and London, 1992.
35. Kuszewski, J.; Nilges, M.; Brunger, A. T. Sampling and efficiency of metric matrix distance geometry: A novel partial metrization algorithm. J. Biomol. NMR 1992, 2, 33-56.
36. Sivasubramanian, S.; Ravichandran, K. Syntheses of o/p- arylthiobenzaldehydes and o/p-methylsulfonylbenzaldehydes. Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem. 1991, 30B, 1148-1149.